ReviewHepatology (Baltimore, Md.)2022
Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?
Review in Hepatology (Baltimore, Md.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Identification and functional validation of SPON2 as a novel biomarker for the diagnosis and prognosis in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2026Article
- Article
- Very Early-Stage Detection Is Associated With Improved Survival in Patients With Unifocal Hepatocellular Carcinoma.Alimentary pharmacology & therapeutics · 2026Article
- Performance of the multi-target hepatocellular carcinoma blood test: Design and rationale of the ALTUS study.Hepatology communications · 2025Article
- Patient-Perceived Risk of Hepatocellular Carcinoma and Net Benefit of Surveillance: A Multicenter Survey Study.The American journal of gastroenterology · 2025Article
- Review
- NSUN5 Facilitates Hepatocellular Carcinoma Progression by Increasing SMAD3 Expression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- National Liver Cancer Screening Trial (TRACER) study protocol.Hepatology communications · 2024Article
- Non-contrast abbreviated MRI for the detection of hepatocellular carcinoma in patients with Liver Imaging Reporting and Data System LR-3 and LR-4 observations in MRI.The British journal of radiology · 2024Article
- Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells.Biomarker research · 2024Article
- Hepatocellular Carcinoma Screening in a Contemporary Cohort of At-Risk Patients.JAMA network open · 2024Article
- Benefits and harms of polygenic risk scores in organised cancer screening programmes: a cost-effectiveness analysis.The Lancet regional health. Western Pacific · 2024Article
- Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy.Nature reviews. Clinical oncology · 2023Review
- Diagnosis and management of indeterminate liver nodules in patients with cirrhosis.Clinical liver disease · 2023Article
- Spherical nucleic acids-based nanoplatforms for tumor precision medicine and immunotherapy.Materials today. Bio · 2023Review
- Article
- Non-alcoholic fatty liver disease-related hepatocellular carcinoma.Journal of liver cancer · 2023Review
- Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.Clinical and molecular hepatology · 2023Review
- Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?Journal of hepatology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Overdiagnosis refers to detection of disease that would not otherwise become clinically apparent during a patient's lifetime. Overdiagnosis is common and has been reported for several cancer types, although there are few studies describing its prevalence in HCC surveillance programs. Overdiagnosis can have serious negative consequences including overtreatment and associated complications, financial toxicity, and psychological harms related to being labeled with a cancer diagnosis. Overdiagnosis can occur for several different reasons including inaccurate diagnostic criteria, detection of premalignant or very early malignant lesions, detection of indolent tumors, and competing risks of mortality. The risk of overdiagnosis is partly mitigated, albeit not eliminated, by several guideline recommendations, including definitions for the at-risk population in whom surveillance should be performed, surveillance modalities, surveillance interval, recall procedures, and HCC diagnostic criteria. Continued research is needed to further characterize the burden and trends of overdiagnosis as well as identify strategies to reduce overdiagnosis in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.